Apratastat
Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC) [1][2]. Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Product Specifications
CAS Number
287405-51-0
Product Name Alternative
TMI-005
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
MMP; TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Neuroscience-Neurodegeneration
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/apratastat.html
Purity
99.29
Solubility
DMSO : ≥ 100 mg/mL
Smiles
CC1(C)[C@H](C(NO)=O)N(S(=O)(C2=CC=C(OCC#CCO)C=C2)=O)CCS1
Molecular Formula
C17H22N2O6S2
Molecular Weight
414.50
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
TNFRSF5/CD40
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Xpress™ Human CAPZB Over-expressing Stable Cell Line
PRKACA Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
